CDXC241220C1000
- 0.00
- 0.000.00%
ChromaDex Newsroom
Insider Purchase: Chief Financial Officer of $CDXC (CDXC) Buys 2,907 Shares
Recent Price Trend in ChromaDex (CDXC) Is Your Friend, Here's Why
ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement
Express News | Watching ChromaDex; Traders Circulate Stock Picked By Zacks Under $10 Newsletter
We Think ChromaDex's (NASDAQ:CDXC) Profit Is Only A Baseline For What They Can Achieve
ChromaDex's Pharmaceutical-Grade Niagen IV Now Accessible at Over 200 Restore Hyper Wellness Clinics Nationwide
Shareholders Can Be Confident That ChromaDex's (NASDAQ:CDXC) Earnings Are High Quality
Roth MKM Maintains ChromaDex(CDXC.US) With Buy Rating, Raises Target Price to $8
ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue?
ChromaDex Analyst Ratings
H.C. Wainwright Maintains ChromaDex(CDXC.US) With Buy Rating, Raises Target Price to $8
ChromaDex's Robust Q3 Performance and Strategic Initiatives Drive 'Buy' Rating With Raised Price Target
Express News | Chromadex Corporation : H.c. Wainwright Raises Target Price to $8 From $6
Market Participants Recognise ChromaDex Corporation's (NASDAQ:CDXC) Revenues Pushing Shares 69% Higher
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript Summary
Trending Stocks Today | Vast Renewables Shoots up 155.5%
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
Dow Jumps 400 Points; US Adds 12,000 Jobs In October
ChromaDex Corp (CDXC) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
ChromaDex Shares Climb on Forecast for 15% Revenue Growth